Bio
Dr. Riaz is dedicated to advancing breast cancer treatment through an innovative clinical trial program that focuses on cutting-edge therapeutics and biomarkers.
Dr. Riaz is studying circulating tumor (ct)DNA-minimal residual disease (MRD) as a pivotal biomarker for early-stage breast cancer. She aims to enhance its use in surveillance and early detection while guiding personalized treatment strategies through novel clinical trials. Furthermore, she is committed to improving immunotherapy efficacy by modifying the tumor microenvironment. Her research involves developing early-phase trials that integrate novel therapeutic approaches, combining immunotherapy and radiotherapy. As a Clinical Assistant Professor at Stanford University School of Medicine, Dr. Riaz is also committed to improving the accessibility of cutting edge therapies to all patients. She is leading a collaborative effort with multiple institutions to develop databases that track patient outcomes and inform treatment practices.
Dr. Riaz’s overarching goal is to expand early-phase clinical trials and foster academic-industry partnerships to advance the field of breast oncology and improve patient care.
